• CBTRUS (Central Brain Tumor Registry of the United States) incidence rates and estimated new cases include all primary malignant and non-malignant tumors of the brain, central nervous system, pituitary and pineal glands, and olfactory tumors of the nasal cavity (including brain lymphoma and leukemia).
  
  
• SEER (Surveillance, Epidemiology, and End Results) program incidence and survival rates extracted from the SEER Cancer Statistics Review, 1975-2007 include primary malignant tumors of the brain and central nervous system (excluding brain lymphoma and leukemia, tumors of the pituitary and pineal gland, and olfactory tumors of the nasal cavity) and, separately, primary non-malignant tumors of the brain and central nervous system.
  
  
• SEER (Surveillance, Epidemiology, and End Results) program survival rates estimated using the SEER Cancer Incidence Research Database, 1973-2007 include all primary malignant tumors of the brain, central nervous system, pituitary and pineal glands, and olfactory tumors of the nasal cavity (including brain lymphoma and leukemia).
  
  
• ACS (American Cancer Society) estimated deaths include primary malignant tumors of the brain and central nervous system (excluding brain lymphoma and leukemia, tumors of the pituitary and pineal glands, and olfactory tumors of the nasal cavity).
  
  
• IARC (International Agency for Research on Cancer) worldwide incidence rates include primary malignant tumors of the brain and central nervous system (excluding brain lymphoma and leukemia, tumors of the pituitary and pineal glands, and olfactory tumors of the nasal cavity). Global rates are age-adjusted using the world standard population. These rates may be compared to other rates adjusted to the world standard population, but they cannot be compared to rates adjusted to other population standards, such as the 2000 United States standard population.
  
  
• Incidence rates are age-adjusted using the 2000 United States standard population unless otherwise noted.
  

• CBTRUS: The incidence rate of all primary non–malignant and malignant brain and central nervous system tumors is 19.3 cases per 100,000 person–years (7.3 per 100,000 person–years for malignant tumors and 12.1 per 100,000 person–years for non-malignant tumors). The rate is higher in females (20.7 per 100,000 person–years) than males (17.9 per 100,000 person–years). ^1a

• CBTRUS: An estimated 64,530 new cases of primary non–malignant and malignant brain and central nervous system tumors are expected to be diagnosed in the United States in 2011. ^1b

• SEER: The incidence rate of primary malignant brain and central nervous system tumors (excluding lymphomas, leukemias, tumors of pituitary and pineal glands, and olfactory tumors of the nasal cavity) for the years 2003-2007 is 6.5 cases per 100,000 person–years. This rate is higher in males (7.6 per 100,000 person–years) than females (5.5 per 100,000 person–years). ^2a

• SEER: The incidence rate of primary non-malignant brain and central nervous system tumors for the years 2004-2007 is 12.3 cases per 100,000 person–years. In contrast to malignant brain and central nervous system tumors, this rate is higher in females (14.6 per 100,000 person–years) than males (9.7 per 100,000 person– years). ^2b

• ACS: An estimated 22,020 new cases of primary malignant brain and central nervous system tumors are expected to be diagnosed in the United States in 2010 (11,980 in males and 10,040 in females). This represents 1.44% of all primary malignant cancers expected to be diagnosed in the United States in 2010. ³

• IARC: The worldwide incidence rate of primary malignant brain and central nervous system tumors in 2002, age–adjusted using the world standard population, is 3.7 per 100,000 person–years in males and 2.6 per 100,000 person–years in females. This represents an estimated 108,277 males and 81,305 females who were diagnosed with a primary malignant brain tumor in 2002, an overall total of 189,582 individuals. The incidence rates are higher in more developed countries (males: 5.8 per 100,000 person–years; females: 4.1 per 100,000 person–years) than in less developed countries (males: 3.0 per 100,000 person–years; females: 2.1 per 100,000 person–years). ⁴

• CBTRUS: CBTRUS has calculated a worldwide estimate of 186,678 newly diagnosed primary non–malignant brain and central nervous system tumors per annum for 2002 (males: n=80,759; females: n=105,918). ⁵

• CBTRUS: The incidence rate of childhood primary non–malignant and malignant brain and central nervous system tumors is 4.8 cases per 100,000 person–years. The rate is higher in males (4.9 per 100,000 person–years) than females (4.8 per 100,000 person–years). ^1a

• CBTRUS: An estimated 4,150 new cases of childhood primary non–malignant and malignant brain and central nervous system tumors are expected to be diagnosed in the United States in 2011. Of these 4,150 new cases, an estimated 2,960 will be in children less than 15 years of age. ^1b

Mortality

• ACS: An estimated 13,140 deaths will be attributed to primary malignant brain and central nervous system tumors in the United States in 2010. ³

Lifetime Risk

• SEER: From birth, males have a 0.7% lifetime risk of ever being diagnosed with a primary malignant brain/central nervous system tumor and 0.5% chance of dying from a brain/central nervous system tumor (excluding lymphomas, leukemias, tumors of pituitary and pineal glands, and olfactory tumors of the nasal cavity). ^2c

• SEER: From birth, females have a 0.5% lifetime risk of ever being diagnosed with a primary malignant brain/central nervous system tumor and a 0.4% chance of dying from a brain/central nervous system tumor (excluding lymphomas, leukemias, tumors of pituitary and pineal glands, and olfactory tumors of the nasal cavity). ^2d

Survival

• SEER: The five–year relative survival rate following diagnosis of a primary malignant brain and central nervous system tumor (including lymphomas and leukemias, tumors of the pituitary and pineal glands, and olfactory tumors of the nasal cavity) is 33.8% for males and 37.5% for females (1995–2007 data). ⁶

• SEER: Five–year relative survival rates following diagnosis of a primary malignant brain and central nervous system tumor (including lymphomas and leukemias, tumors of the pituitary and pineal glands, and olfactory tumors of the nasal cavity) by age of diagnosis (1995–2007 data): ⁶

Age 0-19 years: 72.5%	Age 55-64 years: 17.4%
Age 20-44 years: 56.6%	Age 65-74 years: 9.8%
Age 45-54 years: 31.2%	Age 75 or older: 5.4%

Prevalence

• CBTRUS: The prevalence rate for all primary brain and central nervous system tumors was estimated to be 209.0 per 100,000 in 2004. It was estimated that more than 612,000 persons were living with a diagnosis of primary brain and central nervous system tumor in the United States in 2004 (malignant tumor: more than 124,000 persons; non-malignant tumor: more than 488,000 persons).⁷

• CBTRUS: The prevalence rate for all pediatric (ages 0-19) primary brain and central nervous system tumors was estimated at 35.4 per 100,000 with more than 28,000 children estimated to be living with this diagnosis in the United States in 2004. ⁷